{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:17:57Z","timestamp":1733289477666,"version":"3.30.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00393-024-01576-x","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T20:21:00Z","timestamp":1727814060000},"page":"822-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neues zum Beh\u00e7et-Syndrom","Update on Beh\u00e7et syndrome"],"prefix":"10.1007","volume":"83","author":[{"given":"Ina","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"Ruffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"1576_CR1","doi-asserted-by":"publisher","first-page":"109661","DOI":"10.1016\/j.clim.2023.109661","volume":"253","author":"AF Al-Obeidi","year":"2023","unstructured":"Al-Obeidi\u00a0AF, Nowatzky\u00a0J (2023) Immunopathogenesis of Behcet\u2019s disease. Clin Immunol 253:109661","journal-title":"Clin Immunol"},{"key":"1576_CR2","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1007\/s10620-020-06587-7","volume":"66","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner\u00a0F, Ergelen\u00a0R, Ergenc\u00a0I et\u00a0al (2021) Femoral Vein Wall Thickness Measurement May Be a\u00a0Distinctive Diagnostic Tool to Differentiate Behcet\u2019s Disease with Intestinal Involvement and Crohn\u2019s Disease. Dig Dis Sci 66:2750\u20132755","journal-title":"Dig Dis Sci"},{"key":"1576_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/rheumatology\/keaa264","volume":"60","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner\u00a0F, Ergelen\u00a0R, Yildiz\u00a0Y et\u00a0al (2021) Femoral vein wall thickness measurement: A\u00a0new diagnostic tool for Behcet\u2019s disease. Rheumatology 60:288\u2013296","journal-title":"Rheumatology"},{"issue":"132","key":"1576_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","volume":"39","author":"B Atienza-Mateo","year":"2021","unstructured":"Atienza-Mateo\u00a0B, Beltran\u00a0E, Hernandez-Garfella\u00a0M et\u00a0al (2021) Tocilizumab in Behcet\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol 39(132):37\u201342","journal-title":"Clin Exp Rheumatol"},{"key":"1576_CR5","doi-asserted-by":"publisher","first-page":"2235040","DOI":"10.1080\/09546634.2023.2235040","volume":"34","author":"C Avci","year":"2023","unstructured":"Avci\u00a0C, Akin\u00a0G, Akarsu\u00a0S et\u00a0al (2023) Pyoderma gangrenosum and Behcet\u2019s-like disease induced by secukinumab: a\u00a0paradoxical drug reaction. J\u00a0Dermatolog Treat 34:2235040","journal-title":"J Dermatolog Treat"},{"key":"1576_CR6","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1111\/jdv.16454","volume":"34","author":"N Barrado-Solis","year":"2020","unstructured":"Barrado-Solis\u00a0N, Rodrigo-Nicolas\u00a0B, De La Morena-Barrio\u00a0I et\u00a0al (2020) Report of two cases of Behcet\u2019s disease developed during treatment with secukinumab. J\u00a0Eur Acad Dermatol Venereol 34:e587\u2013e589","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1576_CR7","doi-asserted-by":"publisher","first-page":"152153","DOI":"10.1016\/j.semarthrit.2022.152153","volume":"58","author":"N Barroso-Garcia","year":"2023","unstructured":"Barroso-Garcia\u00a0N, Atienza-Mateo\u00a0B, Ferraz-Amaro\u00a0I et\u00a0al (2023) Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease. Multicenter study of 49\u00a0patients. Semin Arthritis Rheum 58:152153","journal-title":"Semin Arthritis Rheum"},{"key":"1576_CR8","first-page":"599","volume":"24","author":"P Bielefeld","year":"2016","unstructured":"Bielefeld\u00a0P, Devilliers\u00a0H, Deschasse\u00a0C et\u00a0al (2016) Potential of Pegylated Interferon Alpha-2a in Behcet Uveitis: A\u00a0Report of Five Cases. Ocul Immunol Inflamm 24:599\u2013602","journal-title":"Ocul Immunol Inflamm"},{"key":"1576_CR9","doi-asserted-by":"publisher","unstructured":"Burleigh A, Omoyinmi E, Papadopoulou C et al (2023) Genetic testing of Behcet\u2019s disease using next-generation sequencing to identify monogenic mimics and HLA-B*51. Rheumatology, kead628. https:\/\/doi.org\/10.1093\/rheumatology\/kead628 (epub ahead of print)","DOI":"10.1093\/rheumatology\/kead628"},{"key":"1576_CR10","first-page":"116","volume":"19","author":"A Calleja Algarra","year":"2021","unstructured":"Calleja Algarra\u00a0A, Aragon Miguel\u00a0R, Andres Lencina\u00a0JJ et\u00a0al (2021) Behcet\u2019s-like disease during secukinumab treatment: new paradoxical reaction? J\u00a0Dtsch Dermatol Ges 19:116\u2013118","journal-title":"J Dtsch Dermatol Ges"},{"key":"1576_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09273948.2017.1332768","volume":"27","author":"H Celiker","year":"2019","unstructured":"Celiker\u00a0H, Kazokoglu\u00a0H, Direskeneli\u00a0H (2019) Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behcet\u2019s Uveitis: A\u00a0Small Case Series. Ocul Immunol Inflamm 27:15\u201322","journal-title":"Ocul Immunol Inflamm"},{"key":"1576_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/bjd\/ljae051","volume":"190","author":"SR Choi","year":"2024","unstructured":"Choi\u00a0SR, Shin\u00a0A, Ha\u00a0YJ et\u00a0al (2024) All-cause and cause-specific mortality in patients with Behcet disease versus the general population. Br J Dermatol 190:858\u2013866","journal-title":"Br J Dermatol"},{"key":"1576_CR13","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/rheumatology\/keac543","volume":"62","author":"R Deniz","year":"2023","unstructured":"Deniz\u00a0R, Emrence\u00a0Z, Yalcinkaya\u00a0Y et\u00a0al (2023) Improved sensitivity of the skin pathergy test with polysaccharide pneumococcal vaccine antigens in the diagnosis of Behcet disease. Rheumatology 62:1903\u20131909","journal-title":"Rheumatology"},{"key":"1576_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","volume":"97","author":"G Di Scala","year":"2019","unstructured":"Di Scala\u00a0G, Bettiol\u00a0A, Cojan\u00a0RD et\u00a0al (2019) Efficacy of the anti-IL 17 secukinumab in refractory Behcet\u2019s syndrome: A\u00a0preliminary study. J\u00a0Autoimmun 97:108\u2013113","journal-title":"J Autoimmun"},{"key":"1576_CR15","doi-asserted-by":"publisher","first-page":"omz041","DOI":"10.1093\/omcr\/omz041","volume":"2019","author":"E Dincses","year":"2019","unstructured":"Dincses\u00a0E, Yurttas\u00a0B, Esatoglu\u00a0SN et\u00a0al (2019) Secukinumab induced Behcet\u2019s syndrome: a\u00a0report of two cases. Oxf Med Case Reports 2019:omz41","journal-title":"Oxf Med Case Reports"},{"issue":"6","key":"1576_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jid.2023.12.007","volume":"144","author":"I Elhani","year":"2023","unstructured":"Elhani I, Riller Q, Boursier G et al (2023) A20 Haploinsufficiency: A Systematic Review of 177 Cases. J\u00a0Invest Dermatol 144(6):1282\u20131294.e8","journal-title":"J Invest Dermatol"},{"key":"1576_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi\u00a0G, Bettiol\u00a0A, Hatemi\u00a0G et\u00a0al (2024) Behcet\u2019s syndrome. Lancet 403:1093\u20131108","journal-title":"Lancet"},{"key":"1576_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","volume":"79","author":"F Fagni","year":"2020","unstructured":"Fagni\u00a0F, Bettiol\u00a0A, Talarico\u00a0R et\u00a0al (2020) Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet\u2019s phenotype: a\u00a0multicentre study. Ann Rheum Dis 79:1098\u20131104","journal-title":"Ann Rheum Dis"},{"key":"1576_CR19","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi\u00a0G, Mahr\u00a0A, Ishigatsubo\u00a0Y et\u00a0al (2019) Trial of Apremilast for Oral Ulcers in Behcet\u2019s Syndrome. N\u00a0Engl J Med 381:1918\u20131928","journal-title":"N Engl J Med"},{"issue":"6","key":"1576_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, K\u00f6tter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H (2018) 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 77(6):808\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225 (Epub 2018 Apr 6. PMID: 29625968)","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1576_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12519-023-00785-9","volume":"20","author":"D Hu","year":"2024","unstructured":"Hu D, She CH, Bao HF et al (2024) Clinical heterogeneity and five phenotypes identified in pediatric Behcet\u2019s syndrome: a cohort study from Shanghai Behcet\u2019s syndrome database. World J Pediatr 20(8):801\u2013808","journal-title":"World J Pediatr"},{"key":"1576_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/BOR.0000000000000980","volume":"36","author":"U Ilgen","year":"2024","unstructured":"Ilgen\u00a0U (2024) Cluster analysis as a\u00a0clinical and research tool in Behcet\u2019s syndrome. Curr Opin Rheumatol 36:3\u20138","journal-title":"Curr Opin Rheumatol"},{"key":"1576_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Behcet\u2019s D","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Behcet\u2019s D (2014) The International Criteria for Behcet\u2019s Disease (ICBD): a\u00a0collaborative study of 27\u00a0countries on the sensitivity and specificity of the new criteria. J\u00a0Eur Acad Dermatol Venereol 28:338\u2013347","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1576_CR24","doi-asserted-by":"publisher","first-page":"152246","DOI":"10.1016\/j.semarthrit.2023.152246","volume":"62","author":"H Karadeniz","year":"2023","unstructured":"Karadeniz\u00a0H, Ucar\u00a0M, Mammadov\u00a0T et\u00a0al (2023) Diffuse generalized venulitis as the primary pathology of Behcet\u2019s disease: A\u00a0comprehensive magnetic resonance venography study. Semin Arthritis Rheum 62:152246","journal-title":"Semin Arthritis Rheum"},{"key":"1576_CR25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3899\/jrheum.221106","volume":"50","author":"MY Khitri","year":"2023","unstructured":"Khitri\u00a0MY, Bartoli\u00a0A, Maalouf\u00a0G et\u00a0al (2023) Tocilizumab in Behcet Disease: A\u00a0Multicenter Study of 30\u00a0Patients. J\u00a0Rheumatol 50:916\u2013923","journal-title":"J Rheumatol"},{"key":"1576_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1136\/ard-2022-222852","volume":"82","author":"JJ Kuiper","year":"2023","unstructured":"Kuiper\u00a0JJ, Prinz\u00a0JC, Stratikos\u00a0E et\u00a0al (2023) EULAR study group on \u2018MHC-I-opathy\u2019: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis 82:887\u2013896","journal-title":"Ann Rheum Dis"},{"key":"1576_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/09273948.2020.1791346","volume":"30","author":"K Kunimi","year":"2022","unstructured":"Kunimi\u00a0K, Usui\u00a0Y, Asakage\u00a0M et\u00a0al (2022) Anti-TNF-alpha Therapy for Refractory Uveitis Associated with Behcet\u2019s Syndrome and Sarcoidosis: A\u00a0Single Center Study of 131 Patients. Ocul Immunol Inflamm 30:223\u2013230","journal-title":"Ocul Immunol Inflamm"},{"key":"1576_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/03009742.2021.1885735","volume":"50","author":"P Leccese","year":"2021","unstructured":"Leccese\u00a0P, Padula\u00a0MC, Lascaro\u00a0N et\u00a0al (2021) Clinical phenotypes of Behcet\u2019s syndrome in a\u00a0large cohort of Italian patients: focus on gender differences. Scand J Rheumatol 50:475\u2013478","journal-title":"Scand J Rheumatol"},{"key":"1576_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","volume":"74","author":"S Lightman","year":"2015","unstructured":"Lightman\u00a0S, Taylor\u00a0SR, Bunce\u00a0C et\u00a0al (2015) Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet\u2019s disease with upregulation of circulating regulatory T\u00a0cells and reduction of Th17. Ann Rheum Dis 74:1138\u20131144","journal-title":"Ann Rheum Dis"},{"key":"1576_CR30","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1093\/rheumatology\/keac222","volume":"61","author":"J Liu","year":"2022","unstructured":"Liu\u00a0J, Tian\u00a0J, Wang\u00a0Z et\u00a0al (2022) Secukinumab in the treatment of parenchymal neuro-Behcet\u2019s syndrome. Rheumatology 61:e277\u2013e279","journal-title":"Rheumatology"},{"key":"1576_CR31","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.clim.2023.109241","volume":"247","author":"J Liu","year":"2023","unstructured":"Liu\u00a0J, Yu\u00a0X, Wang\u00a0Z et\u00a0al (2023) Baricitinib for the treatment of intestinal Behcet\u2019s disease: A\u00a0pilot study. Clin Immunol 247:109241","journal-title":"Clin Immunol"},{"key":"1576_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jaad.2021.11.045","volume":"87","author":"J London","year":"2022","unstructured":"London\u00a0J, Regent\u00a0A, Dion\u00a0J et\u00a0al (2022) Efficacy and safety of ustekinumab in Behcet disease: Results from the prospective phase\u00a02 STELABEC trial. J\u00a0Am Acad Dermatol 87:681\u2013684","journal-title":"J Am Acad Dermatol"},{"key":"1576_CR33","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1093\/rheumatology\/kead101","volume":"62","author":"F Lotscher","year":"2023","unstructured":"Lotscher\u00a0F, Kerstens\u00a0F, Krusche\u00a0M et\u00a0al (2023) When it looks like Behcet\u2019s syndrome but is something else: differential diagnosis of Behcet\u2019s syndrome: a\u00a0two-centre retrospective analysis. Rheumatology 62:3654\u20133661","journal-title":"Rheumatology"},{"key":"1576_CR34","doi-asserted-by":"crossref","unstructured":"Manole S, Rancea R, Vulturar R et\u00a0al (2023) Frail Silk: Is the Hughes-Stovin Syndrome a\u00a0Behcet Syndrome Subtype with Aneurysm-Involved Gene Variants? Int J Mol Sci 24:","DOI":"10.3390\/ijms24043160"},{"key":"1576_CR35","doi-asserted-by":"publisher","first-page":"108996","DOI":"10.1016\/j.clim.2022.108996","volume":"238","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto\u00a0H, Asano\u00a0T, Tsuchida\u00a0N et\u00a0al (2022) Behcet\u2019s disease with a\u00a0somatic UBA1 variant:Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clin Immunol 238:108996","journal-title":"Clin Immunol"},{"key":"1576_CR36","first-page":"188","volume":"17","author":"J Mchugh","year":"2021","unstructured":"Mchugh\u00a0J (2021) Different phenotypes identified for Behcet syndrome. Nat Rev Rheumatol 17:188","journal-title":"Nat Rev Rheumatol"},{"key":"1576_CR37","doi-asserted-by":"publisher","first-page":"103487","DOI":"10.1016\/j.autrev.2023.103487","volume":"23","author":"M Merashli","year":"2024","unstructured":"Merashli\u00a0M, Bucci\u00a0T, Delgado-Alves\u00a0J et\u00a0al (2024) Relevance of vein wall thickness in Behcet\u2019s disease: A\u00a0systematic review and meta-analysis. Autoimmun Rev 23:103487","journal-title":"Autoimmun Rev"},{"key":"1576_CR38","first-page":"100196","volume":"13","author":"S Oka","year":"2020","unstructured":"Oka\u00a0S, Ono\u00a0K, Nohgawa\u00a0M (2020) The acquisition of trisomy 8 associated with Behcet\u2019s-like disease in myelodysplastic syndrome. Leuk Res Rep 13:100196","journal-title":"Leuk Res Rep"},{"key":"1576_CR39","doi-asserted-by":"publisher","unstructured":"Ordu B, Aslan MS, Ozguler Y et al (2024) Pulmonary artery involvement due to Behcet\u2019s syndrome and Hughes Stovin syndrome: a comparative study. Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/t3i6xc. Online ahead of print","DOI":"10.55563\/clinexprheumatol\/t3i6xc"},{"key":"1576_CR40","first-page":"2048","volume":"41","author":"A Poveda-Gallego","year":"2023","unstructured":"Poveda-Gallego\u00a0A, Chapple\u00a0I, Iacucci\u00a0M et\u00a0al (2023) How to recognise a\u00a0Behcet\u2019s ulcer from other types of oral ulceration? Defining Behcet\u2019s ulceration by an International Delphi Consultation. Clin Exp Rheumatol 41:2048\u20132055","journal-title":"Clin Exp Rheumatol"},{"key":"1576_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00393-023-01371-0","volume":"83","author":"N Ruffer","year":"2024","unstructured":"Ruffer\u00a0N, Krusche\u00a0M, Holl-Ulrich\u00a0K et\u00a0al (2024) Hughes-Stovin syndrome: a\u00a0life-threatening manifestation of Behcet\u2019s syndrome. Z\u00a0Rheumatol 83:327\u2013333","journal-title":"Z Rheumatol"},{"key":"1576_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","volume":"14","author":"E Seyahi","year":"2019","unstructured":"Seyahi\u00a0E (2019) Phenotypes in Behcet\u2019s syndrome. Intern Emerg Med 14:677\u2013689","journal-title":"Intern Emerg Med"},{"issue":"7","key":"1576_CR43","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s10067-024-06995-4","volume":"43","author":"CH She","year":"2024","unstructured":"She CH, Hu D, Zou J et al (2024) Clinical phenotypes of adult-onset Behcet\u2019s syndrome: a comprehensive cross-sectional study in China. Clin Rheumatol 43(7):2261\u20132271","journal-title":"Clin Rheumatol"},{"key":"1576_CR44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/mr\/road012","volume":"34","author":"N Tekgoz","year":"2023","unstructured":"Tekgoz\u00a0N, Tekgoz\u00a0E, Colak\u00a0S et\u00a0al (2023) Age-related differences in the clinical phenotypes of Behcet\u2019s disease: The experience of two referral centres. Mod Rheumatol 34:194\u2013200","journal-title":"Mod Rheumatol"},{"key":"1576_CR45","doi-asserted-by":"publisher","first-page":"151956","DOI":"10.1016\/j.semarthrit.2022.151956","volume":"52","author":"TB Van Der Houwen","year":"2022","unstructured":"Van Der Houwen\u00a0TB, Van Hagen\u00a0PM, Van Laar\u00a0JAM (2022) Immunopathogenesis of Behcet\u2019s disease and treatment modalities. Semin Arthritis Rheum 52:151956","journal-title":"Semin Arthritis Rheum"},{"key":"1576_CR46","doi-asserted-by":"publisher","first-page":"109298","DOI":"10.1016\/j.clim.2023.109298","volume":"250","author":"Z Wang","year":"2023","unstructured":"Wang\u00a0Z, Wang\u00a0X, Liu\u00a0W et\u00a0al (2023) Baricitinib for the treatment of refractory vascular Behcet\u2019s disease. Clin Immunol 250:109298","journal-title":"Clin Immunol"},{"key":"1576_CR47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12519-019-00288-6","volume":"16","author":"MP Yu","year":"2020","unstructured":"Yu\u00a0MP, Xu\u00a0XS, Zhou\u00a0Q et\u00a0al (2020) Haploinsufficiency of A20 (HA20): updates on the genetics, phenotype, pathogenesis and treatment. World J Pediatr 16:575\u2013584","journal-title":"World J Pediatr"},{"key":"1576_CR48","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/rheumatology\/keab840","volume":"61","author":"H Zhong","year":"2022","unstructured":"Zhong\u00a0H, Liu\u00a0T, Liu\u00a0Y et\u00a0al (2022) Efficacy and safety of tocilizumab in Behcet\u2019s syndrome with refractory arterial lesions: a\u00a0single-centre observational cohort study in China. Rheumatology 61:2923\u20132930","journal-title":"Rheumatology"},{"key":"1576_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/ng.3459","volume":"48","author":"Q Zhou","year":"2016","unstructured":"Zhou\u00a0Q, Wang\u00a0H, Schwartz\u00a0DM et\u00a0al (2016) Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48:67\u201373","journal-title":"Nat Genet"},{"key":"1576_CR50","doi-asserted-by":"publisher","first-page":"1759720X2211240","DOI":"10.1177\/1759720X221124014","volume":"14","author":"J Zou","year":"2022","unstructured":"Zou\u00a0J, Cai\u00a0JF, Ye\u00a0JF et\u00a0al (2022) Tofacitinib as an alternative therapy for refractory intestinal Behcet\u2019s syndrome. Ther Adv Musculoskelet Dis 14:1759720X221124014","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1576_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13075-021-02429-7","volume":"23","author":"J Zou","year":"2021","unstructured":"Zou\u00a0J, Luo\u00a0JF, Shen\u00a0Y et\u00a0al (2021) Cluster analysis of phenotypes of patients with Behcet\u2019s syndrome: a\u00a0large cohort study from a\u00a0referral center in China. Arthritis Res Ther 23:45","journal-title":"Arthritis Res Ther"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01576-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01576-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01576-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T08:04:19Z","timestamp":1733213059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01576-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01576-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"27 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0K\u00f6tter: Vortrags- und Beratungshonorare: Abbvie, Amgen, Boehringer, GSK, Janssen, Lilly, Medac, Novartis, Pfizer, Sobi, UCB. M.\u00a0Krusche: Vortrags-und Beratungshonorare: Amgen, Roche\/Chugai, Sanofi, Abbvie, Lilly, Pfizer, Alfasigma, Medac, Sobi, Novartis; Forschungsf\u00f6rderung: Sobi, Sanofi, Novartis, Abbvie. N.\u00a0Ruffer gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}